Published in Bone on July 25, 2013
Osteoclasts: more than 'bone eaters'. Trends Mol Med (2014) 1.17
Osteoclasts-Key Players in Skeletal Health and Disease. Microbiol Spectr (2016) 0.88
Association of genetic polymorphisms with osteosarcoma risk: a meta-analysis. Int J Clin Exp Med (2015) 0.79
Kinetics of gene expression and bone remodelling in the clinical phase of collagen-induced arthritis. Arthritis Res Ther (2015) 0.79
Osteoclast TGF-β Receptor Signaling Induces Wnt1 Secretion and Couples Bone Resorption to Bone Formation. J Bone Miner Res (2015) 0.79
Extracellular Membrane Vesicles Derived from 143B Osteosarcoma Cells Contain Pro-Osteoclastogenic Cargo: A Novel Communication Mechanism in Osteosarcoma Bone Microenvironment. Transl Oncol (2014) 0.77
CCL7 is a protective factor secreted by mechanically loaded osteocytes. J Dent Res (2014) 0.77
FTY-720P Suppresses Osteoclast Formation by Regulating Expression of Interleukin-6 (IL-6), Interleukin-4 (IL-4), and Matrix Metalloproteinase 2 (MMP-2). Med Sci Monit (2016) 0.75
Transforming Growth Factor β1 (TGF-β1) in the Sera of Postmenopausal Osteoporotic Females. Int J Endocrinol Metab (2016) 0.75
A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet (2005) 9.62
TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med (2009) 4.58
Transforming growth factor-beta1 to the bone. Endocr Rev (2005) 3.13
Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med (1996) 2.92
Circulating transforming growth factor-beta in Marfan syndrome. Circulation (2009) 2.69
Products of activated lymphocytes: leukocyte inhibitory factor (LIF) distinct from migration inhibitory factor (MIF). J Immunol (1974) 2.53
Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci U S A (2008) 2.39
The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol (2004) 2.19
Inhibition of TGF-beta receptor signaling in osteoblasts leads to decreased bone remodeling and increased trabecular bone mass. Development (1999) 1.69
TGF-beta coordinately activates TAK1/MEK/AKT/NFkB and SMAD pathways to promote osteoclast survival. Exp Cell Res (2008) 1.69
Mutations in the gene encoding the latency-associated peptide of TGF-beta 1 cause Camurati-Engelmann disease. Nat Genet (2000) 1.63
TIEG1 null mouse-derived osteoblasts are defective in mineralization and in support of osteoclast differentiation in vitro. Mol Cell Biol (2005) 1.56
Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NFkappaB pathways to maintain osteoclast survival. J Cell Biochem (2003) 1.53
Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia. Nature (2008) 1.52
A role for TGFbeta(1) in osteoclast differentiation and survival. J Cell Sci (2000) 1.47
Congenic mice provide in vivo evidence for a genetic locus that modulates intrinsic transforming growth factor β1-mediated signaling and bone acquisition. J Bone Miner Res (2012) 1.41
Differential roles of Smad2 and Smad3 in the regulation of TGF-β1-mediated growth inhibition and cell migration in pancreatic ductal adenocarcinoma cells: control by Rac1. Mol Cancer (2011) 1.30
Elevated CXCL16 expression by synovial macrophages recruits memory T cells into rheumatoid joints. Arthritis Rheum (2005) 1.29
Osteoblastic responses to TGF-beta during bone remodeling. Mol Biol Cell (1998) 1.28
Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation. J Cell Physiol (2004) 1.28
CCL9/MIP-1gamma and its receptor CCR1 are the major chemokine ligand/receptor species expressed by osteoclasts. J Cell Biochem (2002) 1.27
TRB3 interacts with SMAD3 promoting tumor cell migration and invasion. J Cell Sci (2011) 1.27
Type I insulin-like growth factor receptor signaling in skeletal muscle regeneration and hypertrophy. J Musculoskelet Neuronal Interact (2007) 1.26
Osteoclast synthesis and secretion and activation of latent transforming growth factor beta. J Bone Miner Res (1994) 1.22
Expression of CXCR6 and its ligand CXCL16 in the lung in health and disease. Clin Exp Allergy (2005) 1.22
Plasminogen-dependent activation of latent transforming growth factor beta (TGF beta) by growing cultures of osteoblast-like cells. J Cell Physiol (1993) 1.18
Osteoblastogenesis regulation signals in bone remodeling. Osteoporos Int (2012) 1.08
Transforming growth factor beta inhibits bone resorption in fetal rat long bone cultures. J Clin Invest (1988) 1.06
TGFBI-promoted adhesion, migration and invasion of human renal cell carcinoma depends on inactivation of von Hippel-Lindau tumor suppressor. Urology (2012) 1.00
Cytokines in muscle damage. Adv Clin Chem (2012) 0.98
TGF-β1-dependent L1CAM expression has an essential role in macrophage-induced apoptosis resistance and cell migration of human intestinal epithelial cells. Oncogene (2012) 0.98
Type III TGF-β receptor enhances colon cancer cell migration and anchorage-independent growth. Neoplasia (2011) 0.96
The type III transforming growth factor-β receptor inhibits proliferation, migration, and adhesion in human myeloma cells. Mol Biol Cell (2011) 0.95
The neurotrophins act synergistically with LIF and members of the TGF-beta superfamily to promote the survival of spiral ganglia neurons in vitro. Hear Res (1999) 0.94
Reelin is involved in transforming growth factor-β1-induced cell migration in esophageal carcinoma cells. PLoS One (2012) 0.94
Leucocyte migration inhibition factor (LIF) production by lymphocytes of normal children, newborns, and children with immune deficiency. Clin Exp Immunol (1976) 0.92
Sphingosine 1-phosphate (S1P) receptors 1 and 2 coordinately induce mesenchymal cell migration through S1P activation of complementary kinase pathways. J Biol Chem (2013) 0.91
TGF-β mediates suppression of adipogenesis by estradiol through connective tissue growth factor induction. Endocrinology (2011) 0.90
A recombinant human TGF-beta1 fusion protein with collagen-binding domain promotes migration, growth, and differentiation of bone marrow mesenchymal cells. Exp Cell Res (1999) 0.90
Comparative effects of TGF-β2/Smad2 and TGF-β2/Smad3 signaling pathways on proliferation, migration, and extracellular matrix production in a human lens cell line. Exp Eye Res (2011) 0.89
Effect of platelet-rich plasma on migration and proliferation of SaOS-2 osteoblasts: role of platelet-derived growth factor and transforming growth factor-beta. Wound Repair Regen (2006) 0.86
Regulation of proliferation and migration in retinoic acid treated C3H10T1/2 cells by TGF-beta isoforms. J Cell Physiol (2005) 0.85
Inhibition of dendritic cell migration by transforming growth factor-β1 increases tumor-draining lymph node metastasis. J Exp Clin Cancer Res (2012) 0.84
LIF: not just a leukemia inhibitory factor. Endocr Rev (1991) 0.83
TGF-β isoforms inhibit IGF-1-induced migration and regulate terminal differentiation in a cell-specific manner. J Muscle Res Cell Motil (2011) 0.82
Induction of LIF-mRNA by TGF-beta 1 in Schwann cells. Brain Res (1997) 0.81
Lipopolysaccharide disrupts the directional persistence of alveolar myofibroblast migration through EGF receptor. Am J Physiol Lung Cell Mol Physiol (2012) 0.81
RLIM interacts with Smurf2 and promotes TGF-β induced U2OS cell migration. Biochem Biophys Res Commun (2011) 0.80
Circulating CXCL16 is not related to circulating oxLDL in patients with rheumatoid arthritis. Biochem Biophys Res Commun (2007) 0.79
Dexamethasone inhibits TGF-β2-induced migration of human lens epithelial cells: implications for posterior capsule opacification prevention. Mol Med Rep (2012) 0.78
Modulation of PDGF mediated osteoblast chemotaxis by leukemia inhibitory factor (LIF). J Cell Physiol (1996) 0.78
Differential effects of TGF-β and FGF-2 on in vitro proliferation and migration of primate retinal endothelial and Müller cells. Acta Ophthalmol (2011) 0.78
lin-Sca-1+ cells and age-dependent changes of their proliferation potential are reliant on mesenchymal stromal cells and are leukemia inhibitory factor dependent. Gerontology (2008) 0.77
Leukaemia inhibitory factor and bone cell function. Ciba Found Symp (1992) 0.76
RGTA modulates the healing pattern of a defect in a monolayer of osteoblastic cells by acting on both proliferation and migration. J Biomed Mater Res A (2003) 0.76
DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med (2006) 7.90
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2007) 6.76
Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev (2002) 6.38
Osteoporosis: now and the future. Lancet (2011) 5.81
Circulating osteoblast-lineage cells in humans. N Engl J Med (2005) 4.19
Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. J Bone Miner Res (2004) 4.02
Sarcoma derived from cultured mesenchymal stem cells. Stem Cells (2006) 3.40
Fat tissue, aging, and cellular senescence. Aging Cell (2010) 3.34
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest (2003) 3.09
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev (2007) 2.82
A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. J Bone Miner Res (2008) 2.76
Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2008) 2.57
Building bone to reverse osteoporosis and repair fractures. J Clin Invest (2008) 2.40
Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci U S A (2008) 2.39
Effects of suppression of follicle-stimulating hormone secretion on bone resorption markers in postmenopausal women. J Clin Endocrinol Metab (2010) 2.33
For estimating creatinine clearance measuring muscle mass gives better results than those based on demographics. Kidney Int (2009) 2.32
Observing the quantization of zero mass carriers in graphene. Science (2009) 2.18
Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res (2005) 2.15
Contribution of in vivo structural measurements and load/strength ratios to the determination of forearm fracture risk in postmenopausal women. J Bone Miner Res (2007) 2.11
Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res (2008) 2.07
Bone turnover across the menopause transition: correlations with inhibins and follicle-stimulating hormone. J Clin Endocrinol Metab (2006) 2.04
The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev (2005) 2.03
Update on Wnt signaling in bone cell biology and bone disease. Gene (2011) 2.03
Age-dependence of femoral strength in white women and men. J Bone Miner Res (2010) 2.03
Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res (2011) 2.00
Structural determinants of vertebral fracture risk. J Bone Miner Res (2007) 1.97
Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol (2012) 1.94
Histone deacetylase 3 interacts with runx2 to repress the osteocalcin promoter and regulate osteoblast differentiation. J Biol Chem (2004) 1.91
Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2009) 1.90
In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res (2014) 1.90
Mechanisms of sex steroid effects on bone. Biochem Biophys Res Commun (2005) 1.89
Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab (2010) 1.87
Runx2: a master organizer of gene transcription in developing and maturing osteoblasts. Birth Defects Res C Embryo Today (2005) 1.84
FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. Cancer Res (2011) 1.80
Estrogen receptor isoform-specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ERalpha or ERbeta. J Cell Biochem (2003) 1.76
Bone structure at the distal radius during adolescent growth. J Bone Miner Res (2009) 1.74
The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis. Endocrinology (2010) 1.74
Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium. Proc Natl Acad Sci U S A (2013) 1.70
TGF-beta coordinately activates TAK1/MEK/AKT/NFkB and SMAD pathways to promote osteoclast survival. Exp Cell Res (2008) 1.69
Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets (2009) 1.61
Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR workshop. J Bone Miner Res (2009) 1.59
Role of circulating osteogenic progenitor cells in calcific aortic stenosis. J Am Coll Cardiol (2012) 1.59
Mesenchymal stem cells for bone repair and metabolic bone diseases. Mayo Clin Proc (2009) 1.59
Age- and sex-specific differences in the factor of risk for vertebral fracture: a population-based study using QCT. J Bone Miner Res (2006) 1.58
Lymphoid enhancer factor-1 and beta-catenin inhibit Runx2-dependent transcriptional activation of the osteocalcin promoter. J Biol Chem (2003) 1.57
TIEG1 null mouse-derived osteoblasts are defective in mineralization and in support of osteoclast differentiation in vitro. Mol Cell Biol (2005) 1.56
Osteocalcin expression by circulating endothelial progenitor cells in patients with coronary atherosclerosis. J Am Coll Cardiol (2008) 1.55
Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res (2011) 1.53
Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NFkappaB pathways to maintain osteoclast survival. J Cell Biochem (2003) 1.53
Histone deacetylase inhibitors promote osteoblast maturation. J Bone Miner Res (2005) 1.51
Effects of estrogen with micronized progesterone on cortical and trabecular bone mass and microstructure in recently postmenopausal women. J Clin Endocrinol Metab (2013) 1.51
Emerging therapeutic opportunities for skeletal restoration. Nat Rev Drug Discov (2011) 1.48
Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem (2003) 1.48
Estrogen receptor alpha and beta heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells. Mol Endocrinol (2005) 1.48
Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res (2002) 1.46
Estrogen and the skeleton. Trends Endocrinol Metab (2012) 1.46
Changes in Runx2/Cbfa1 expression and activity during osteoblastic differentiation of human bone marrow stromal cells. J Bone Miner Res (2003) 1.42
Histone deacetylase 7 associates with Runx2 and represses its activity during osteoblast maturation in a deacetylation-independent manner. J Bone Miner Res (2008) 1.42
Fracture risk following bilateral orchiectomy. J Urol (2003) 1.41
Remodeling and vascular spaces in bone. J Bone Miner Res (2007) 1.39
Relationship of age to bone microstructure independent of areal bone mineral density. J Bone Miner Res (2012) 1.37
Effect of blockade of TNF-alpha and interleukin-1 action on bone resorption in early postmenopausal women. J Bone Miner Res (2007) 1.35
Large area and structured epitaxial graphene produced by confinement controlled sublimation of silicon carbide. Proc Natl Acad Sci U S A (2011) 1.33
Relation of vertebral deformities to bone density, structure, and strength. J Bone Miner Res (2010) 1.32
Increasing options for the treatment of osteoporosis. N Engl J Med (2009) 1.32
Nonoxidative free fatty acid disposal is greater in young women than men. J Clin Endocrinol Metab (2010) 1.31
Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts. Bone (2011) 1.30
Androgen therapy in women: an Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab (2006) 1.30
Histone deacetylase 3 depletion in osteo/chondroprogenitor cells decreases bone density and increases marrow fat. PLoS One (2010) 1.29
Effects of loss of steroid receptor coactivator-1 on the skeletal response to estrogen in mice. Endocrinology (2003) 1.28
Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation. J Cell Physiol (2004) 1.28
Restoring theta-like rhythmicity in rats restores initial learning in the Morris water maze. Hippocampus (2006) 1.28
Fracture risk after bilateral oophorectomy in elderly women. J Bone Miner Res (2003) 1.28
Contributions of bone density and structure to fracture risk assessment in men and women. Osteoporos Int (2005) 1.27
Characterization of circulating osteoblast lineage cells in humans. Bone (2007) 1.27
Robust QCT/FEA models of proximal femur stiffness and fracture load during a sideways fall on the hip. Ann Biomed Eng (2010) 1.26
A bone structural basis for fracture risk in diabetes. J Clin Endocrinol Metab (2008) 1.26
Bone morphogenic protein 2 directly enhances differentiation of murine osteoclast precursors. J Cell Biochem (2010) 1.26
Higher muscle protein synthesis in women than men across the lifespan, and failure of androgen administration to amend age-related decrements. FASEB J (2008) 1.24
Population-based analysis of the relationship of whole bone strength indices and fall-related loads to age- and sex-specific patterns of hip and wrist fractures. J Bone Miner Res (2005) 1.24
Regulation of gene expression in osteoblasts. Biofactors (2010) 1.23
Skeletal effects of estrogen are mediated by opposing actions of classical and nonclassical estrogen receptor pathways. J Bone Miner Res (2005) 1.23
Cortical porosity identifies women with osteopenia at increased risk for forearm fractures. J Bone Miner Res (2014) 1.21
High serum IGFBP-2 is predictive of increased bone turnover in aging men and women. J Bone Miner Res (2007) 1.21
Effect of 2 years of testosterone replacement on insulin secretion, insulin action, glucose effectiveness, hepatic insulin clearance, and postprandial glucose turnover in elderly men. Diabetes Care (2007) 1.20
MicroRNA functions in osteogenesis and dysfunctions in osteoporosis. Curr Osteoporos Rep (2013) 1.19
Effects of estrogen on osteoprogenitor cells and cytokines/bone-regulatory factors in postmenopausal women. Bone (2011) 1.19
Female reproductive system and bone. Arch Biochem Biophys (2010) 1.19
Osteoporosis assessment by whole body region vs. site-specific DXA. Osteoporos Int (2005) 1.17
Histone deacetylases in skeletal development and bone mass maintenance. Gene (2010) 1.16